Remove scales to expedite healing

Penetration Optimized Exuvimax Technology 
quickly lifts scales 
improving conditions for effective dermatosis 
topical treatments.

Penetration Optimized Exuvimax Technology

Exuvimax Technology
Exuvimax Technology2018-12-04T19:59:21+00:00

How it Works

When applied to scale, this patented formulation provides
the special creeping and spreading property.

How it Works

The creeping and spreading property allows LOYON®
to flow into the intercorneocytic space.

How it Works

This quickly loosens and gently dissociates scale
at the junction of the corneodesmosomes.

What are the key benefits of Exuvimax?

  • Exuvimax’s key benefit is to remove scale and therefore allow the topical treatments to work more effectively and faster on the underlying condition.

  • A subsequent anti-inflammatory therapy with topical corticosteroids can be started at the earliest possible time using Exuvimax.

  • Fast-acting: Studies show Exuvimax has a statistically significant keratolysis and a reduction of scale severity observed within 3-7 days of treatment.

  • Safe and Gentle: No risk for toxicity; safe and gentle for use on patients of all ages.

Success with Exuvimax

A Study

Removal of Scaling in Infants and Children with Cradle Cap (Infantile Seborrheic Dermatitis)1

  • 20 Patients – Treatment: 8 days – Primary criteria: scaling and treatment success (improvement of at least 2 steps on the scaling score [0-3])1
  • 80% of subjects had a reduction from moderate or severe to either none, very mild or mild in scaling1
  • 50% of subjects achieved improvement by at least 2 points, after treatment days 2, 3 & 41
  • No spot bleedings, no safety concerns1

Patient 1

Patient 1 BeforePatient 1 After

Before & after 4 days with 3 applications of Loyon®

Patient 2

Patient 2 BeforePatient 2 After

Before & after 10 days with 3 applications of Loyon®

Exuvimax In Action

Clinical Trial2


Title:
Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device (LOYON®) in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis

Objective: To assess the efficacy and tolerability of a dimeticone-based product in removal of scales in patients with psoriasis corporis/capitis under real-life conditions

Participants: n=40 (70% psoriasis capitis, 30% psoriasis corporis)

Treatment: Once daily

Patient 1

Patient 3 BeforePatient 3 After

Before & after 4 days with 3 applications of Loyon®

Change of scaling score during treatment period2

  • Loyon® showed a statistically significant decrease in scaling score, with a relative reduction in scaling of 36.8% after 7 days of treatment for psoriasis capitis patients.2 (See Figure 1)
  • Treatment success was achieved in 76.8% of patients with psoriasis capitis, and time to treatment success was evaluated to be 4.14 days for these patients.2

  • Due to its viscosity and creeping and spreading properties, Loyon® readily flows underneath and between the corneocytes and removes scaling.2

Scaling Score

Figure 1: Change of scaling score during treatment period

Responder analysis during treatment period2

  • The distribution of scaling severity resulted in an increase of mild or very mild psoriasis capitis from:2 (See Figure 2)
    — 18.4% at baseline
    — 63.2% after 3 days
    — 95.3% after 7 days, and
    — 4.7% free of scaling after 7 days.
  • Severe scaling was completely reduced to 0% after 3 days of treatment with LOYON® decreased from 26.3% at baseline to 0%.2
  • LOYON® showed a statistically significant reduction of PSSI after 3 days of treatment.2

Responder analysis during treatment period

Figure 2: Responder analysis during treatment period

References: 1. Hengge U. Topical, non-medicated LOYON® in facilitating the removal of scaling in infants and children with cradle cap: a proof-of-concept pilot study. Dermatol Ther. 2014;4:221-232. 2. Hengge U, et al. Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or capitis. Psoriasis: Targets & Therapy. 2017;7:41-49.